Based upon available information, Handa believes that it is the first applicant to file an abbreviated new drug application (ANDA) for Seroquel XR containing a paragraph IV certification, under the provisions of the Hatch- Waxman Act.
Should its ANDA be approved by the FDA, Handa believes that its product will be entitled to 180 days of generic market exclusivity.